ZA200703697B - Use of ranolazone in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure - Google Patents

Use of ranolazone in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure

Info

Publication number
ZA200703697B
ZA200703697B ZA200703697A ZA200703697A ZA200703697B ZA 200703697 B ZA200703697 B ZA 200703697B ZA 200703697 A ZA200703697 A ZA 200703697A ZA 200703697 A ZA200703697 A ZA 200703697A ZA 200703697 B ZA200703697 B ZA 200703697B
Authority
ZA
South Africa
Prior art keywords
remodeling
ranolazone
treatment
combination
heart failure
Prior art date
Application number
ZA200703697A
Other languages
English (en)
Inventor
Blackburn Brent
Sabbah Hani
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of ZA200703697B publication Critical patent/ZA200703697B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200703697A 2004-11-09 2007-05-08 Use of ranolazone in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure ZA200703697B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62615404P 2004-11-09 2004-11-09

Publications (1)

Publication Number Publication Date
ZA200703697B true ZA200703697B (en) 2008-09-25

Family

ID=35892429

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200703697A ZA200703697B (en) 2004-11-09 2007-05-08 Use of ranolazone in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure

Country Status (15)

Country Link
US (2) US20060111361A1 (xx)
EP (1) EP1809289A1 (xx)
JP (1) JP2008519770A (xx)
KR (1) KR20070084063A (xx)
CN (1) CN101072562A (xx)
AU (1) AU2005304421A1 (xx)
BR (1) BRPI0517650A (xx)
CA (1) CA2586840A1 (xx)
IL (1) IL183056A0 (xx)
MX (1) MX2007005367A (xx)
NO (1) NO20072934L (xx)
RU (1) RU2007121707A (xx)
SG (1) SG156681A1 (xx)
WO (1) WO2006053161A1 (xx)
ZA (1) ZA200703697B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2486712C (en) * 2002-05-21 2012-01-03 Cv Therapeutics, Inc. Method of treating diabetes
JP5522663B2 (ja) * 2006-09-08 2014-06-18 カーディオポリマーズ， インコーポレイテッド 全体的な心臓のサイズ変更および再形成のための心筋内パターン形成
US20090012413A1 (en) * 2006-09-08 2009-01-08 Sabbah Hani N Cardiac patterning for improving diastolic function
CA2670651A1 (en) * 2006-12-21 2008-07-03 Cv Therapeutics, Inc. Reduction of cardiovascular symptoms
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
JP2010518170A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 冠微小血管疾患の処置のためのラノラジンの使用
EP2136780A1 (en) * 2007-02-13 2009-12-30 CV Therapeutics Inc. Use of ranolazine for the treatment of cardiovascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
AU2008239681B2 (en) * 2007-04-11 2013-10-03 Henry Ford Health System Cardiac repair, resizing and reshaping using the venous system of the heart
KR20100033490A (ko) * 2007-05-31 2010-03-30 질레드 팔로 알토 인코포레이티드 상승된 뇌-형 나트륨이뇨 펩티드에 대한 라놀라진
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
JP2011010865A (ja) 2009-06-30 2011-01-20 Ikaria Holdings Inc 肺高血圧の臨床的または超音波心臓検査上の証拠を伴う低酸素性呼吸器不全に罹った満期産およびほぼ満期産の新生児を治療する方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033967T2 (de) * 1989-06-23 2002-12-19 Syntex (U.S.A.) Llc, Palo Alto Ranolazin und verwandte Piperazine zur Behandlung von Schockzuständen
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6323226B1 (en) * 1999-10-19 2001-11-27 Texas Heart Institute Treatment of heart disease with cox-2 inhibitors
EP2033633A3 (en) * 2000-02-18 2009-07-08 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
AU2001277938A1 (en) * 2000-07-21 2002-02-05 Cv Therapeutics, Inc. Method for treating angina
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias

Also Published As

Publication number Publication date
AU2005304421A1 (en) 2006-05-18
WO2006053161A8 (en) 2006-09-14
EP1809289A1 (en) 2007-07-25
KR20070084063A (ko) 2007-08-24
RU2007121707A (ru) 2008-12-20
JP2008519770A (ja) 2008-06-12
CN101072562A (zh) 2007-11-14
SG156681A1 (en) 2009-11-26
US20090176772A1 (en) 2009-07-09
WO2006053161A1 (en) 2006-05-18
NO20072934L (no) 2007-08-08
MX2007005367A (es) 2007-06-18
BRPI0517650A (pt) 2008-10-14
IL183056A0 (en) 2007-10-31
CA2586840A1 (en) 2006-05-18
US20060111361A1 (en) 2006-05-25

Similar Documents

Publication Publication Date Title
ZA200703697B (en) Use of ranolazone in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
PL1912650T3 (pl) Zastosowanie flibanseryny w leczeniu otyłości
EP1814628A4 (en) MEDIUM VOLTAGE THERAPY APPLICATIONS FOR TREATMENT OF HEART DISENESS
PT1978947E (pt) Derivados nitro-óxido para utilização no tratamento de distrofias musculares
EP1814909A4 (en) USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP1711191A4 (en) CHLORINE IN THE TREATMENT OF NEURODEEGENERATIVE DISEASES
EP1731113A4 (en) MEDICAL TREATMENT KIT
EP1758605A4 (en) PROUROGUANYLIN AS THERAPEUTIC AND DIAGNOSTIC AGENTS
EP1874800A4 (en) DIAGNOSTIC AND THERAPEUTIC AGENTS
HK1137352A1 (en) Therapeutic use of at least one botulic neurotoxin in the treatment of pain induced by at least one antineoplastic agent
ZA200701193B (en) The use of N-aryl diazaspiracyclic compounds in the treatment of addiction
WO2009156182A3 (de) Uracilderivate und deren verwendung
SI2148667T1 (sl) Uporaba derivatov cikloheksanheksola pri zdravljenju okularnih bolezni
IL179560A0 (en) Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias
PL2012816T3 (pl) Zastosowanie tymozyny 1, samej lub w kombinacji z ptx3 lub gancyklowirem, do leczenia zakażenia cytomegalowirusem
EP1924326A4 (en) REDUCTION OF MYOKARD DAMAGE AND INCIDENCE OF ARRHYTHMIES FROM LOSS, REDUCTION, OR INTERRUPTION OF CORONARY BLOOD FLOW
ZA200709542B (en) Combination therapy in the treatment of cancer
EP1952833A4 (en) CLOSED TYPE BLOOD STORAGE TANK AND EXTRACORPORAL BLOOD CIRCULATION SYSTEM USING SAID TANK
ZA200610297B (en) Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias
GB2411834B (en) Composition for use in the treatment of dry skin conditions
EP2214634A4 (en) SKIN MOISTURIZER, PROMOTER OF BLOOD CIRCULATION, AND EXTERNAL SKIN PRODUCTS CONTAINING MOISTURIZER FOR THE SKIN AND THE PROMOTER OF BLOOD CIRCULATION
PL1732487T3 (pl) Plaster medyczny do stosowania na skórę
PT2182954T (pt) Utilização de ácidos nor-biliares no tratamento de arteriosclerose
EP1951914A4 (en) DIAGNOSTIC AND THERAPEUTIC METHODS AND AGENTS
WO2007012066A3 (en) TRUNCATED OXIDIZED THYMOSIN β4 AND DERIVATIVES THEREOF